Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05425576 · ClinicalTrials.gov registry record · Phase 2
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
A Phase 2 study, sponsored by Oncotelic.
- Not yet
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT05425576 is a Phase 2 study that has not yet begun recruiting, run by Oncotelic. The registered enrollment target is 63 participants.
The verdict
NCT05425576, a Phase 2 study, has not yet begun recruiting, sponsored by Oncotelic.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.
Interventions
- DRUG OT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2025-06 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05425576
The ClinicalTrials.gov registry entry for NCT05425576 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncotelic, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OT-101 is the first listed.
NCT05425576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05425576 about?
NCT05425576 is a clinical study titled "OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition". This is a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.
What is the current status of trial NCT05425576?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2025-06. Estimated completion is 2029-12.
What interventions are being tested in trial NCT05425576?
The interventions under investigation include: OT-101 (DRUG).
Who is sponsoring clinical trial NCT05425576?
This trial is sponsored by Oncotelic, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.